Cargando…
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved patients’ outcomes and paved the way for the beginning of advent of targeted approaches in breast ca...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Research Foundation
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376449/ https://www.ncbi.nlm.nih.gov/pubmed/22720269 http://dx.doi.org/10.3389/fonc.2012.00062 |